Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Chief Scientific Officer | September 25, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tectonic Therapeutic, Inc.
Report date September 25, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,305 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-25 · Tax withholding · Disposed 444 · Balance 54,841 F1: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025. Row 2 · 2026-09-30 · Sale · Disposed 536 · Balance 54,305 F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $23.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025.
F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $23.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 01:00 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 536 | $23.04 | $12,349.44 |
DisclosureSEC source: 0002023255-26-000012 · form4-10022026_091039.xml · nonDerivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,305 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $23.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2026 Filed Oct 3, 2026 01:00 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Tax withholdingCommon Stock | 444 | $23.67 | $10,509.48 |
DisclosureSEC source: 0002023255-26-000012 · form4-10022026_091039.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,841 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $29.92 | $0.00 |
DisclosureSEC source: 0002023255-26-000011 · form4-09082026_040907.xml · derivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2036-09-02 F1 · derivative.exercise_date: 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 20:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 43 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0002023255-26-000009 · form4-08262026_040801.xml · derivative · entry 3 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,787 Underlying: Common Stock · 43 shares Expires 2035-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 20:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 43 | $36.52 | $1,570.36 |
DisclosureSEC source: 0002023255-26-000009 · form4-08262026_040801.xml · nonDerivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,285 F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 20:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 43 | $14.71 | $632.53 |
DisclosureSEC source: 0002023255-26-000009 · form4-08262026_040801.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:25 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 43 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0002023255-26-000007 · form4-08142026_110840.xml · derivative · entry 3 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 43 shares Expires 2035-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:25 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 43 | $35.00 | $1,505.00 |
DisclosureSEC source: 0002023255-26-000007 · form4-08142026_110840.xml · nonDerivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,285 F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:25 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 43 | $14.71 | $632.53 |
DisclosureSEC source: 0002023255-26-000007 · form4-08142026_110840.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:19 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 172 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0002023255-26-000006 · form4-07012026_090747.xml · derivative · entry 3 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,873 Underlying: Common Stock · 172 shares Expires 2035-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:19 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 172 | $35.00 | $6,020.00 |
DisclosureSEC source: 0002023255-26-000006 · form4-07012026_090747.xml · nonDerivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,285 F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:19 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 172 | $14.71 | $2,530.12 |
DisclosureSEC source: 0002023255-26-000006 · form4-07012026_090747.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 22:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 215 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0002023255-26-000005 · form4-03092026_100314.xml · derivative · entry 6 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,045 Underlying: Common Stock · 215 shares Expires 2035-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F4 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 22:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0002023255-26-000005 · form4-03092026_100314.xml · derivative · entry 5 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,959 Underlying: Common Stock · 2,500 shares Expires 2031-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. F3 · price: Received in exchange for a stock option to acquire 71,029 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml F2 · derivative.exercise_date: 25% of the shares subject to the option vested on June 1, 2022; and the remainder of the shares subject to the option vest in 36 equal monthly installments with the final amount vesting on June 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 22:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 215 | $35.00 | $7,525.00 |
DisclosureSEC source: 0002023255-26-000005 · form4-03092026_100314.xml · nonDerivative · entry 4 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,285 F1 · kind: These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 22:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 6,047 | $30.00 | $181,410.00 |
DisclosureSEC source: 0002023255-26-000005 · form4-03092026_100314.xml · nonDerivative · entry 3 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,500 F1 · kind: These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 22:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 215 | $14.71 | $3,162.65 |
DisclosureSEC source: 0002023255-26-000005 · form4-03092026_100314.xml · nonDerivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 22:12 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 2,500 | $2.38 | $5,950.00 |
DisclosureSEC source: 0002023255-26-000005 · form4-03092026_100314.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $27.41 | $0.00 |
DisclosureSEC source: 0002023255-26-000004 · form4-03052026_100302.xml · derivative · entry 4 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2036-03-03 F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 1,650 | $25.00 | $41,250.00 |
DisclosureSEC source: 0002023255-26-000004 · form4-03052026_100302.xml · nonDerivative · entry 3 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,832 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002023255-26-000004 · form4-03052026_100302.xml · nonDerivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,482 F2 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | SaleCommon Stock | 1,649 | $22.06 | $36,376.94 |
DisclosureSEC source: 0002023255-26-000004 · form4-03052026_100302.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,482 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| February 04, 2026 Filed Feb 10, 2026 21:06 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Tax withholdingCommon Stock | 1,748 | $23.22 | $40,588.56 |
DisclosureSEC source: 0002023255-26-000002 · form4-02102026_090217.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,131 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:35 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,000 | Not disclosed Strike: $2.98 | Not disclosed |
DisclosureSEC source: 0002023255-25-000005 · form4-12292025_041201.xml · derivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,065 Underlying: Common Stock · 7,000 shares Expires 2032-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Received in exchange for a stock option to acquire 60,000 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on June 27, 2022, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:35 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 7,000 | $2.98 | $20,860.00 |
DisclosureSEC source: 0002023255-25-000005 · form4-12292025_041201.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 21:00 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,260 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0002023255-25-000003 · form4-09292025_050907.xml · derivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,260 Underlying: Common Stock · 8,260 shares Expires 2035-09-24 F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 21:00 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 4,550 | $0.00 | $0.00 |
DisclosureSEC source: 0002023255-25-000003 · form4-09292025_050907.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,879 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:05 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 27,530 | $0.00 Strike: $48.01 | $0.00 |
DisclosureSEC source: 0001415889-25-003228 · form4-02062025_040208.xml · derivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,530 Underlying: Common Stock · 27,530 shares Expires 2035-02-03 F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on March 4, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:05 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 15,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003228 · form4-02062025_040208.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,329 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of February 4, 2026, February 4, 2027 and February 4, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:32 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,500 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-028404 · form4-12052024_091203.xml · derivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,459 Underlying: Common Stock · 34,459 shares Expires 2031-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Received in exchange for a stock option to acquire 71,029 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on June 1, 2022; and the remainder of the shares subject to the option vest in 36 equal monthly installments with the final amount vesting on June 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:32 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | Exercise / conversionCommon Stock | 3,500 | $2.38 | $8,330.00 |
DisclosureSEC source: 0001415889-24-028404 · form4-12052024_091203.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:20 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017962 · form4-06242024_080611.xml · derivative · entry 5 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2034-06-19 F9 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:20 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,704 | Not disclosed Strike: $5.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-017962 · form4-06242024_080611.xml · derivative · entry 4 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,704 Underlying: Common Stock · 18,704 shares Expires 2033-11-30 F2 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F8 · price: Received in exchange for a stock option to acquire 35,000 shares of Tectonic common stock pursuant to the Merger Agreement. F7 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on December 1, 2023, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:20 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,065 | Not disclosed Strike: $2.98 | Not disclosed |
DisclosureSEC source: 0001415889-24-017962 · form4-06242024_080611.xml · derivative · entry 3 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,065 Underlying: Common Stock · 32,065 shares Expires 2032-06-26 F2 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F6 · price: Received in exchange for a stock option to acquire 60,000 shares of Tectonic common stock pursuant to the Merger Agreement. F5 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on June 27, 2022, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:20 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,959 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-017962 · form4-06242024_080611.xml · derivative · entry 2 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,959 Underlying: Common Stock · 37,959 shares Expires 2031-06-27 F2 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F4 · price: Received in exchange for a stock option to acquire 71,029 shares of Tectonic common stock pursuant to the Merger Agreement. F3 · derivative.exercise_date: 25,796 of the shares subject to the option are immediately exercisable. The remainder of the shares subject to the option vest in 12 equal monthly installments beginning on July 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:20 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 10,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017962 · form4-06242024_080611.xml · nonDerivative · entry 1 McNamara Peter · CIK 0002023255 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,688 F1 · price: Received in exchange for 20,000 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.